Adaptimmune Therapeutics (ADAP) Announces Lift of FDA Partial Clinical Hold on NY‑ESO SPEAR in MRCLS
Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced that the U.S. Food and Drug Administration has removed the partial clinical hold on ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)